Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B.

Lampertico P, Viganò M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, Boninsegna S, Farci P, Fargion S, Giuberti T, Iannacone C, Regep L, Massetto B, Facchetti F, Colombo M; PegBeLiver Study Group..

Gut. 2013 Feb;62(2):290-8. doi: 10.1136/gutjnl-2011-301430. Epub 2012 Aug 2.

PMID:
22859496
2.

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group..

N Engl J Med. 2005 Jun 30;352(26):2682-95.

3.

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group..

N Engl J Med. 2004 Sep 16;351(12):1206-17.

4.

Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.

Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY.

J Dig Dis. 2013 Aug;14(8):446-50. doi: 10.1111/1751-2980.12065.

PMID:
23615131
5.

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.

Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Brunetto MR, Farci P, Popescu M, McCloud P; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group..

Gut. 2007 May;56(5):699-705. Epub 2006 Nov 24.

6.

Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study.

Kim BH, Lee YJ, Kim W, Yoon JH, Jung EU, Park SJ, Kim YJ, Lee HS.

Scand J Gastroenterol. 2012 Sep;47(8-9):1048-55. doi: 10.3109/00365521.2012.694902. Epub 2012 Jun 25.

PMID:
22726105
7.

Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients.

Caruntu FA, Streinu-Cercel A, Gheorghe LS, Grigorescu M, Sporea I, Stanciu C, Andronescu D, Voinea F, Diculescu M, Oproiu A, Voiosu R.

J Gastrointestin Liver Dis. 2009 Dec;18(4):425-31.

8.

[Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].

Yue W, Yuan H, Mao XR, Deng YD, Chen L.

Zhonghua Gan Zang Bing Za Zhi. 2013 Mar;21(3):184-8. Chinese.

PMID:
23967738
9.

Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients.

Chen CH, Lee CM, Hung CH, Wang JH, Hu TH, Changchien CS, Lu SN.

J Gastroenterol Hepatol. 2011 Mar;26(3):461-8. doi: 10.1111/j.1440-1746.2010.06429.x.

PMID:
21332543
10.

Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).

Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M.

J Hepatol. 2014 Oct;61(4):777-84. doi: 10.1016/j.jhep.2014.05.044. Epub 2014 Jun 7.

PMID:
24915612
11.

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P.

Hepatology. 2009 Apr;49(4):1141-50. doi: 10.1002/hep.22760.

PMID:
19338056
12.

Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.

Huang Z, Deng H, Zhao Q, Zheng Y, Peng L, Lin C, Zhao Z, Gao Z.

Eur J Gastroenterol Hepatol. 2013 Oct;25(10):1165-9. doi: 10.1097/MEG.0b013e3283612e95.

PMID:
23571612
13.

Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.

Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, Rothe V, Regep L, Bonino F.

J Hepatol. 2013 Dec;59(6):1153-9. doi: 10.1016/j.jhep.2013.07.017. Epub 2013 Jul 18.

PMID:
23872601
14.

Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response.

Sonneveld MJ, Zoutendijk R, Flink HJ, Zwang L, Hansen BE, Janssen HL.

Clin Infect Dis. 2013 Jan;56(1):100-5. doi: 10.1093/cid/cis859. Epub 2012 Oct 5.

15.

Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.

Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.

PLoS One. 2015 Apr 2;10(4):e0122259. doi: 10.1371/journal.pone.0122259. eCollection 2015.

16.

A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B.

Piccolo P, Lenci I, di Paolo D, Demelia L, Sorbello O, Nosotti L, Angelico M.

Antivir Ther. 2013;18(1):57-64. doi: 10.3851/IMP2281. Epub 2012 Aug 7.

PMID:
22872648
17.

Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort.

Wiegand J, Brosteanu O, Kullig U, Wiese M, Berr F, Maier M, Tillmann HL, Schiefke I.

Z Gastroenterol. 2011 Nov;49(11):1463-9. doi: 10.1055/s-0031-1281582. Epub 2011 Nov 8.

PMID:
22069045
18.

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.

Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL.

Gastroenterology. 2008 Aug;135(2):459-67. doi: 10.1053/j.gastro.2008.05.031. Epub 2008 May 15.

PMID:
18585385
19.

Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.

Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, Buster EH, Uitterlinden AG, Hansen BE, Chan HL, Janssen HL.

Gastroenterology. 2012 Mar;142(3):513-520.e1. doi: 10.1053/j.gastro.2011.11.025. Epub 2011 Nov 19.

PMID:
22108195
20.

A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.

Gish RG, Lau DT, Schmid P, Perrillo R.

Am J Gastroenterol. 2007 Dec;102(12):2718-23. Epub 2007 Jul 27.

PMID:
17662102

Supplemental Content

Support Center